<DOC>
	<DOCNO>NCT01854658</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind , parallel group , chronic-dosing ( 24 week ) , placebo-controlled study ass efficacy safety Glycopyrrolate ( GP Formoterol Fumarate ( FF ) combination metered-dose inhaler ( MDI ) ( GFF ; PT003 ) , GP MDI ( PT001 ) , FF MDI ( PT005 ) compare Placebo MDI subject moderate severe COPD .</brief_summary>
	<brief_title>Multi-Center Study Assess Efficacy Safety PT003 , PT005 , PT001 Subjects With Moderate Very Severe COPD ( PINNACLE 2 )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>Key Male female subject least 40 year age old 80 Visit 1 . Subjects establish clinical history COPD define American Thoracic Society ( ATS ) /European Respiratory Society ( ERS ) Current former smoker history least 10 packyears cigarette smoking . Subjects FEV1/FVC ratio &lt; 0.70 FEV1 &lt; 80 % predict normal ≥750 mL FEV1 &lt; 30 % predict normal value . Subjects willing , opinion investigator , able adjust current COPD therapy require protocol Key Significant diseases COPD , i.e . disease condition , opinion investigator , may put patient risk participation study may influence either result study subject 's ability participate study Current diagnosis asthma alpha1 antitrypsin deficiency Other active pulmonary disease active tuberculosis , lung cancer , bronchiectasis , sarcoidosis , idiopathic interstitial pulmonary fibrosis , primary pulmonary hypertension , uncontrolled sleep apnea Hospitalized due poorly control COPD within 3 month prior screen Screening Period Poorly control COPD , define acute worsen COPD require treatment oral corticosteroid antibiotic within 6 week prior screen Screening Period Lower respiratory tract infection require antibiotic within 6 week prior screen Screening Period Unstable ischemic heart disease , leave ventricular failure , document myocardial infarction within 12 month enrollment . Recent history acute coronary syndrome , percutaneous coronary intervention , coronary artery bypass graft within past three month Congestive heart failure ( CHF NYHA Class III/IV ) Clinically significant abnormal 12lead ECG Abnormal liver function test define AST , ALT , total bilirubin ≥ 1.5 time upper limit normal Visit 1 repeat test Cancer complete remission least five year History hypersensitivity β2agonists , glycopyrronium muscarinic anticholinergic , lactose/milk protein component MDI Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>